All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The SOT Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the SOT Hub cannot guarantee the accuracy of translated content. The SOT Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Solid Organ Transplantation Hub is an independent medical education platform, sponsored by Therakos. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View solid organ transplantation content recommended for you
Results from a retrospective study evaluating post-transplant cardiovascular complications (CVC) and associated risk factors in pediatric patients who underwent kidney transplantation at a tertiary center in Israel between 2014 and 2024 were published in Pediatric Nephrology by Pollack et al. The primary outcomes were post-transplant CVCs, defined as a composite endpoint including the occurrence of one or more of the following during follow-up: hypertension requiring pharmacologic treatment, left ventricular hypertrophy (LVH), reduced left ventricular ejection fraction, or aortic root enlargement.
Key data: After a median follow-up of 7.3 years, the most common CVC in pediatric kidney transplant recipients (N = 72) was post-transplant hypertension (41.6%; n = 72). Among recipients of living donor grafts (n = 29) intensified immunosuppression therapy was associated with greater predicted probability of CVC in multivariable logistic regression analysis (adjusted odds ratio [aOR], 9.87; 95% confidence interval [CI], 1.03–95.6; p = 0.047). In contrast, donor type had minimal impact on CVC risk among patients who did not require intensified immunosuppressive therapy (aOR, 0.81; 95% CI, 0.24–2.56; p = 0.715). No demographic, dialysis-related, or transplant-related variables were independently associated with CVC.
Key learning: This study suggests that the combination of living donor transplantation and intensified immunosuppressive therapy may be associated with post-transplant CVC, highlighting the importance of cardiovascular surveillance in pediatric kidney transplant recipients with high immunologic risk profiles; however, larger prospective studies are needed to clarify the relationship and long-term implications of post-transplant cardiovascular risk and to guide targeted prevention strategies.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
Your opinion matters
Which of the following additional evidence do you think would have the greatest impact on clinicians’ choice to adopt ECP in SOT?